LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/FDA Clears Stryker 3D Expandable Interbody System
Legal & Regulatory and Reimbursement

FDA Clears Stryker 3D Expandable Interbody System

November 20, 2019 2 min read Premium comments

Advertisement

FDA Clears Stryker 3D Expandable Interbody System
Sahara Lateral 3D Expandable Interbody System / Courtesy of Stryker Corp.
#510clearance#strykerSecondary#spinefusion

Stryker Corporation has received 510(k) clearance for its Sahara Lateral 3D Expandable Interbody System featuring Lamellar 3D Titanium Technology. The system came to Stryker with its acquisition of K2M, Inc.

First Ever 3D-Printed Lateral Expandable Device

In a November 1, 2019 press release, the company stated the device is the “first ever 3D-printed lateral expandable fusion device and features passive expansion capabilities that are designed to allow surgeons to achieve up to 30 degrees of sagittal spinal correction in skeletally mature patients.”

The implant, according to the company, utilizes a passive expansion mechanism. “The implant can either be adjusted from a lateral approach intraoperatively or can adjust passively in a staged posterior approach following osteotomy.”

According to the October 3, 2019 FDA clearance document, Sahara implants are indicated “for use with autograft and/or allogenic bone graft comprised of cancellous and/or corticancellous bone graft when used as an adjunct to fusion in patients with degenerative disc disease at one level or two contiguous levels from L2 to S1.”

“The implants can also be used as an adjunct to fusion in patients diagnosed with degenerative scoliosis.”

“Hyperlordotic and Lateral implants must be used with supplemental fixation cleared for use in the lumbar spine, in addition to the provided bone screws.”

The company added that the Sahara Lateral “complements the Sahara Anterior Lumbar Expandable Stabilization System, a lordotic expandable device with integrated screw fixation.” The device is available in a variety of footprints, heights and lordotic offerings “designed to more precisely match a patient’s anatomy.”

Advertisement

Lamellar 3D Titanium

Lamellar 3D Titanium Technology uses a 3D printing method that starts with a titanium powder. The implants are grown through the selective application of a high-energy laser beam, incorporating complex internal geometries and a roughened surface architecture. Roughened titanium surfaces, according to the company, have been shown to demonstrate increased protein expression in contrast to smooth titanium surfaces.

Eric Major, K2M’s co-founder and current President of Stryker’s Spine Division, said the Sahara Lateral “provides surgeons and hospital systems with a 3D-printed solution for complex posterior correction maneuvers, all while reinforcing our commitment to excellence in medical innovation and improving quality of life for people with spinal deformities.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy